Key result
Glycoprotein IIb/IIIa inhibitors prevent platelet aggregation and exert further biological functions, though large-scale studies comparing their efficacy and safety are lacking.
This review highlights the potential pleiotropic effects of GPIIb/IIIa antagonists beyond platelet aggregation, suggesting a possible role in vascular repair.
Answers are grounded in this paper and cite their sources.
Potential pleiotropic effects of GPIIb/IIIa inhibitors remain hypothesis-generating; large comparative trials are needed to define any clinical role.
Background: The use of inhibitors of glycoprotein IIb/IIIa (GPIIb/IIIa) has provided dramatic results in terms of the prevention of acute stent thrombosis and a reduction in major adverse coronary events in patients subjected to percutaneous coronary intervention. GPIIb/IIIa or αIIbβ3 is a member of the β3 subfamily of integrins, which also includes αVβ3. GPIIb/IIIa functions as a receptor for fibrinogen and several adhesion proteins sharing an arginine-glycine-aspartic acid (RGD) sequence. GPIIb/IIIa antagonists, through blockade of the receptor, prevent platelet aggregation. Among the three GPIIb/IIIa antagonists used in therapy, abciximab is an anti-β3 monoclonal antibody, while tirofiban and eptifibatide mimic the binding sequence of the fibrinogen ligand. Although antiplatelet aggregation represents the central function of GPIIb/IIIa inhibitors, further actions have been documented for these compounds. Objective: The aim of the present article is to review the structures and functions of GPIIb/IIIa antagonists and to highlight the clinical outcomes and results of randomized trials with these compounds. Hypotheses on the unexplored potential of GPIIb/IIIa antagonists will be put forward. Conclusion: GPIIb/IIIa inhibitors were developed to prevent platelet aggregation, however, these compounds can exert further biological functions, both platelet- and non-platelet-related. Large-scale studies comparing the efficacy and safety of GPIIb/IIIa antagonists are lacking. More insights into the functions of these compounds may lead to generation of novel small molecules able to antagonize platelet aggregation while promoting vascular repair.
No takes yet. Share an insight, caveat, or question.
Giordano et al. (2016) conducted a review in percutaneous coronary intervention. Glycoprotein IIb/IIIa Antagonists was evaluated. Glycoprotein IIb/IIIa inhibitors prevent platelet aggregation and exert further biological functions, though large-scale studies comparing their efficacy and safety are lacking.
Synapse has enriched 10 related papers. Consider them for comparative context: